- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00466882
Use of the INAMED LAPBAND System to Reduce BMI's in Obese Renal Failure Patients
Issues Related to the Use of the INAMED LAPBAND SYSTEM to Reduce BMI's in Obese Renal Failure Patients Needing Renal Transplantation: A Pilot Study
Studieöversikt
Detaljerad beskrivning
The concern of transplant surgeons is that obese patients with high BMI's are more likely to experience post-transplantation complications than age-matched recipients [1]. Nevertheless, the Summa transplant list contains numerous patients with renal failure that have BMI's above 35. These patients are not considered to be "active" transplant candidates because of their obesity and are not eligible to receive a kidney transplant. Dr. Lal counsels these patients that they must lose weight in order to be considered active candidates for transplantation.
Weight loss for obese patients in renal failure is difficult. These patients must undergo hemodialysis three times weekly. Most of these patients do not, or physically cannot, engage in exercise activities. Many of these patients are burdened psychologically, and further behavioral responsibilities related to weight loss may overstress them. Repetitive diets or behavioral therapy in morbidly obese patients prior to transplantation have had disappointing results [2]. Likewise, pharmacological management of obesity in these patients is largely unsuccessful. Noradrenergic appetite suppressants must be restricted because of stimulatory side-effects. Serotonergic agents have cardiovascular and pulmonary complications. Thermogenic agents are minimally effective [2].
The INAMED LAPBAND SYSTEM is an FDA-approved, surgically-placed device marketed to facilitate weight reduction in obese individuals. The LAPBAND is positioned laparoscopically around the stomach and requires an overnight hospitalization and an upper GI swallow the next morning. The device can be gradually adjusted to increase stomach constriction by the physician in an office setting so that the patient loses approximately 1-2 pounds per week over two years. These adjustments are performed on average 4-5 times during the first year and twice during the second year.
The purpose of this pilot study is to assess the utility of the LAPBAND in facilitating weight loss in obese renal failure patients awaiting transplantation and to document issues related to its use in these patients. The hope is that the LAPBAND will facilitate enough weight loss to reduce the patient's BMI to 35 or below after placement of the LAPBAND. If the patient reaches the intended goal of BMI of 35, they will be placed on the active renal transplant list and will be eligible for transplantation.
A secondary goal of this research is to follow those patients who successfully reach BMI's of 35 or less who are subsequently transplanted to determine any untoward effects of the LAPBAND upon transplantation success
Studietyp
Kontakter och platser
Studieorter
-
-
Ohio
-
Akron, Ohio, Förenta staterna, 44304
- Summa Health System
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- 18 or older
- Hemodialysis patient with BMI between 36 and 42
Exclusion Criteria:
- Patients undergoing peritoneal dialysis
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Övrig
- Tidsperspektiv: Retrospektiv
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Inamed Lap-Band System
The LAPBAND is positioned laparoscopically around the stomach and requires an overnight hospitalization and an upper GI swallow the next morning.
The device can be gradually adjusted to increase stomach constriction by the physician in an office setting so that the patient loses approximately 1-2 pounds per week over two years.
|
Patient's will be seen in the physician's office one week post surgery and once a month thereafter.
The device can be gradually adjusted by the insertion of a needle into the port and saline is added or removed to inflate or deflate the LAPBAND.
This can be conducted in the physician's office setting to enable the patient to lose 1-2 pounds per week over two years.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Weight Loss
Tidsram: 2 years
|
Assess weight loss after surgery
|
2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Transplantation Success
Tidsram: 2 years
|
Assess possible effects of weight loss surgery on transplantation success
|
2 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: John Zografakis, MD, Summa Health System
- Huvudutredare: Tanamay Lal, MD, Summa Health System
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- INAMED
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Fetma
-
SanionaAvslutadHypothalamic Injury-induced Obesity (HIO)Danmark
Kliniska prövningar på Inamed Lap-Band System
-
Apollo Endosurgery, Inc.Avslutad
-
Apollo Endosurgery, Inc.AvslutadDödlig fetmaFörenta staterna
-
InamedMassachusetts Veterans Epidemiology Research and Information CenterOkändInflammation | Leverfunktion | Glykemisk kontroll | Epworth Sleepiness Scale | Järn- och benomsättning | SF-36 | IW-QOL Lite HRQoL
-
NYU Langone HealthHope FoundationAvslutad
-
University of Texas Southwestern Medical CenterAvslutad
-
Jeffrey L Zitsman, MDAvslutadObstruktivt sömnapnésyndrom | Metaboliskt syndrom | Insulinresistens | Dödlig fetma | Alkoholfri fettleversjukdomFörenta staterna
-
Apollo Endosurgery, Inc.AvslutadFetmaStorbritannien, Australien, Förenta staterna, Italien, Kanada, Belgien
-
University of California, IrvineAvslutadDödlig fetmaFörenta staterna
-
Vectorious Medical Technologies Ltd.Har inte rekryterat ännu
-
Vectorious Medical Technologies Ltd.Rekrytering